Product Description
Ulevostinag is a synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ulevostinag)
Mechanisms of Action: STING Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Brazil, France, Israel, Korea, Norway, Spain, United Kingdom, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Head and Neck Cancer|Squamous Cell Carcinoma
Phase 1: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Phase 2 Study in 1L HNSCC of IT MK-1454 / MK-3475 IV vs MK-3475 IV | P2 |
Temporarily not available |
Head and Neck Cancer |
2025-02-06 |
|
| MK-1454-002 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2022-09-30 |
|
| MK-1454-001 | P1 |
Completed |
Lymphoma |
2022-04-21 |